Vertex Pharmaceuticals Inc: (NASD: VRTX)

$77.38

-2.11 (-2.65%)

Volume 2,069,736

May 20 04:00 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 77.08 - 79.58
52wk Low - High 38.44 - 87.47
Previous Close 79.49
Avg. Volume 4,100,642
Industry MED-BIOMED/GENE
Market Cap 17.34 B
Div - Yield 0.00 - 0.00
Beta 0.30
PE (Forward) 0.00
Current Year Est. -2.13
Quarterly Earnings ESP 0.00%

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Rank Change Trend3

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Neutral

Zacks Industry Rank

91 out of 265

Equity Research Report

Updated as of 05/14/2013

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

PE (Forward) NA
PEG Ratio NA
Current Year Est. -2.13
Current Quarter Estimate -0.21
Most Accurate Estimate -0.21
Earnings ESP 0.00%
Next Earnings Report Date 08-05-2013
EPS Last Year 0.13
Expected Earnings Growth 19.00%

Company Description

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

VRTX Chart by YCharts

Earnings Estimates

Current Qtr
(06/2013)
Next Qtr
(09/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate -0.21 -0.26 -2.13 -1.42
Number of Estimates 7 7 10 10
Low Estimate -0.32 -0.38 -2.56 -2.69
High Estimate -0.12 -0.19 -1.00 NA
Year Ago EPS 0.33 0.00 0.68 -2.13
EPS Growth -162.77% NA -412.79% 33.29%

Average Earnings Estimates for VRTX

EPS Growth for VRTX

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
VERTEX PHARM VRTX 79.49
AETERNA ZENTARS AEZS 2.10
ANIKA THERAPEUT ANIK 14.40
GENTIUM SPA-ADR GENT 8.87
AASTROM BIOSCI ASTM 0.57
ACHILLION PHARM ACHN 7.77
ADDEX THERA LTD ADDXF 6.94
AFFYMAX INC AFFY 1.33
ALEXION PHARMA ALXN 102.90
ALKERMES INC ALKS 31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Financials

EPS TTM 0.13
Sales 1,527
Net Income -507
Price/Earnings 611.46
Price/Book 18.49
Price/Cash Flow 95.79
Price/Sales 12.24

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.